NCT01811875View on ClinicalTrials.gov

Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

PHASE4TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 21, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Haemophilia A
Interventions
BIOLOGICAL

Optivate 500IU

Trial Locations (4)

64546

HZRM Haemophilia Centre Rhine Main, Darmstadt

80-216

Fundacion BIOS, Barranquilla

32-102

Hospital general de Medellin, Medellín

93-513

Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz

Sponsors
All Listed Sponsors
lead

Bio Products Laboratory

OTHER